Can a CT scan predict who will benefit from lung cancer chemoimmunotherapy?

NCT ID NCT07559123

Recruiting now Knowledge-focused Sponsor: Samsung Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether features on CT scans can predict how well non-small cell lung cancer responds to chemoimmunotherapy given before surgery. Researchers will compare CT images taken before and after treatment with the actual results from surgery. The goal is to develop a noninvasive tool to guide treatment decisions and reduce unnecessary side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: High-resolution deep learning-based CT reconstruction
What this could lead to: If successful, this could lead to a noninvasive way to identify which lung cancer patients are most likely to benefit from chemoimmunotherapy before surgery, helping tailor treatment and avoid unnecessary side effects.
What could go wrong: This is an observational study, not a treatment trial, so it won't directly change patient care yet. The imaging biomarkers may not prove accurate enough in larger or more diverse groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CT NEOADJUVANT CHEMOIMMUNOTHERAPY NSCLC

Contacts and locations

Locations

Samsung Medical Center
RECRUITING

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.